| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | ANAPC1; TSG24; Anaphase-promoting complex subunit 1; APC1; Cyclosome subunit 1; Mitotic checkpoint regulator; Testis-specific gene 24 protein |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human APC1 around the phosphorylation site of Ser355. AA range:321-370 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets ANAPC1 and detects endogenous levels of ANAPC1 protein. Only detects the phosphorylated form of ANAPC1.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | ANAPC1 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~216.5 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human APC1 around the phosphorylation site of Ser355. AA range:321-370 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 64682; Mouse: 17222 |
| UniProt | Q9H1A4 (Human: Q9H1A4; Mouse: P53995) |
Scientific Background
ANAPC1 (anaphase promoting complex subunit 1) encodes a subunit of the anaphase-promoting complex. This complex is an E3 ubiquitin ligase that regulates progression through the metaphase to anaphase portion of the cell cycle by ubiquitinating proteins which targets them for degradation.
Alternative Names
ANAPC1; TSG24; Anaphase-promoting complex subunit 1; APC1; Cyclosome subunit 1; Mitotic checkpoint regulator; Testis-specific gene 24 protein
Safety & Handling
| Target | ANAPC1 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Molecular Weight | ~216.5 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human APC1 around the phosphorylation site of Ser355. AA range:321-370 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 64682; Mouse: 17222 |
| UniProt | Q9H1A4 (Human: Q9H1A4; Mouse: P53995) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
ANAPC1 (anaphase promoting complex subunit 1) encodes a subunit of the anaphase-promoting complex. This complex is an E3 ubiquitin ligase that regulates progression through the metaphase to anaphase portion of the cell cycle by ubiquitinating proteins which targets them for degradation.
Alternative Names
ANAPC1; TSG24; Anaphase-promoting complex subunit 1; APC1; Cyclosome subunit 1; Mitotic checkpoint regulator; Testis-specific gene 24 protein
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
